Rosiglitazone reduces hepatic fat content

Rosiglitazone reduces hepatic fat content

Opis bibliograficzny
Główni autorzy:	Buckingham, R, Toseland, C, Draper, N, Clarke, K
Format:	Journal article
Wydane:	2000

Podobne zapisy

Rosiglitazone prevents ischaemic injury in the obese Zucker rat heart
od: Sidell, R, i wsp.
Wydane: (2001)

Leukemia and rosiglitazone
od: Irfan Yavasoglu, i wsp.
Wydane: (2016-03-01)

Sirt1 and Sirt6 mediate beneficial effects of rosiglitazone on hepatic lipid accumulation.
od: Soo Jin Yang, i wsp.
Wydane: (2014-01-01)

Rosiglitazone treatment improves cardiac efficiency in hearts from diabetic mice.
od: How, O, i wsp.
Wydane: (2007)

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.
od: Kahn, SE, i wsp.
Wydane: (2006)

The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction.
od: Lygate, C, i wsp.
Wydane: (2003)

Rosiglitazone-associated fractures in type 2 diabetes
od: Kahn, SE, i wsp.
Wydane: (2008)

Possible modulation of the antidiabetic effect of rosiglitazone by buspirone
od: Wafaa R. Mohamed, i wsp.
Wydane: (2012-06-01)

Incidence of diabetes following ramipril or rosiglitazone withdrawal
od: Holman, R, i wsp.
Wydane: (2011)

Rosiglitazone reduces diabetes angiopathy by inhibiting mitochondrial dysfunction dependent on regulating HSP22 expression
od: Lingling Yu, i wsp.
Wydane: (2023-04-01)

Guidance on rosiglitazone for type 2 diabetes mellitus.
od: Matthews, DR
Wydane: (2001)

Incidence of diabetes following ramipril or rosiglitazone withdrawal.
od: Investigators, D
Wydane: (2011)

Isolation, Synthesis and Characterization of Rosiglitazone Maleate Impurities
od: Singamsetty Radha Krishna, i wsp.
Wydane: (2008-01-01)

Budget impact of rosiglitazone in type 2 diabetes
od: Orietta Zaniolo, i wsp.
Wydane: (2007-03-01)

Safety and efficacy of rosiglitazone in the elderly diabetic patient
od: Adie Viljoen, i wsp.
Wydane: (2009-04-01)

The autophagic regulation of rosiglitazone-promoted adipocyte browning
od: Yue Li, i wsp.
Wydane: (2024-06-01)

Hepatic Angiomyolipoma with Minimal Intratumoral Fat Content
od: Masataka Banshodani, i wsp.
Wydane: (2009-11-01)

Rosiglitazone , Metformin or both for Treatment of Polycystic Ovary Syndrome
od: Mohammed A.Taher, i wsp.
Wydane: (2017-03-01)

Rosiglitazone , Metformin or both for Treatment of Polycystic Ovary Syndrome
od: Mohammed A.Taher, i wsp.
Wydane: (2017-03-01)

Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
od: Colin R Dormuth, i wsp.
Wydane: (2009-06-01)

RP-HPLC Method for the Simultaneous Estimation of Rosiglitazone and Gliclazide in Tablets
od: G. Rathinavel, i wsp.
Wydane: (2009-01-01)

Rosiglitazone ameliorates diffuse axonal injury by reducing loss of tau and up-regulating caveolin-1 expression
od: Yong-lin Zhao, i wsp.
Wydane: (2016-01-01)

Effect of Rosiglitazone on Coronary Angiogenesis in Diabetic and Control Rats
od: Ensieh Salehi, i wsp.
Wydane: (2011-06-01)

Rosiglitazone as an option for patients with acromegaly: a case series
od: Bahena-García Ana, i wsp.
Wydane: (2011-05-01)

Simpson's paradox visualized: The example of the Rosiglitazone meta-analysis
od: Schumacher Martin, i wsp.
Wydane: (2008-05-01)

The impact of acute rosiglitazone on insulin pharmacokinetics at the blood‐brain barrier
od: Demi C. Galindo, i wsp.
Wydane: (2020-07-01)

High Concentrations of Rosiglitazone Reduce mRNA and Protein Levels of LRP1 in HepG2 Cells
od: Alejandro N. Rondón-Ortiz, i wsp.
Wydane: (2017-11-01)

Correction: Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin.
od: Colin R. Dormuth, i wsp.
Wydane: (2010-01-01)

Lipid metabolome-wide effects of the PPARγ agonist rosiglitazones⃞
od: Steven M. Watkins, i wsp.
Wydane: (2002-11-01)

Preventive effects of Salvia officinalis leaf extract on insulin resistance and inflammation in a model of high fat diet-induced obesity in mice that responds to rosiglitazone
od: Mohamed R. Ben Khedher, i wsp.
Wydane: (2018-01-01)

Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria
od: Rosauro Varo, i wsp.
Wydane: (2017-05-01)

Co-Administration of Conjugated Linoleic Acid and Rosiglitazone Increases Atherogenic Co-Efficient and Alters Isoprenaline-Induced Vasodilatation in Rats Fed High Fat Diet
od: Chai, Boon Kheng, i wsp.
Wydane: (2018)

Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats.
od: Soo Jin Yang, i wsp.
Wydane: (2011-01-01)

Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet.
od: Vladimir Kus, i wsp.
Wydane: (2011-01-01)

Protective effect of rosiglitazone on kidney function in high-fat challenged human-CRP transgenic mice: a possible role for adiponectin and miR-21?
od: Martine C. Morrison, i wsp.
Wydane: (2017-06-01)

Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
od: Lachin, J, i wsp.
Wydane: (2011)

Prenatal Rosiglitazone Administration to Neonatal Rat Pups Does Not Alter the Adult Metabolic Phenotype
od: Hernan Sierra, i wsp.
Wydane: (2012-01-01)

Correction: Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin
Wydane: (2010-01-01)

Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
od: Zinman, B, i wsp.
Wydane: (2010)

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
od: Tan, G, i wsp.
Wydane: (2005)